Vertex Pharmaceuticals

Yahoo Finance • yesterday

2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The r... Full story

Yahoo Finance • 3 days ago

Fortune Reveals the 100 Most Powerful Women in Business 2026 List

Jane Fraser, Chair and CEO of Citigroup, leads Fortune's 29th annual Most Powerful Women in Business list Women driving change across AI, finance, energy, and health care are among this year's top honorees Half of the women on the list r... Full story

Yahoo Finance • 5 days ago

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?

Key Points CRISPR Therapeutics has an approved product and several gene editing medicines in development. Beam Therapeutics is exploring ways to develop safer gene-editing therapies. One of these stocks is a lot less risky than the other.... Full story

Yahoo Finance • 9 days ago

Polycystic Kidney Disease Market Analysis Report 2026-2036, Profiles of Key Players - Otsuka Pharmaceutical, Novartis, Pfizer, and Vertex Pharmaceuticals

Company Logo The global polycystic kidney disease (PKD) market is expanding rapidly due to rising prevalence, advanced treatments, and increased awareness. The growing cases of chronic kidney diseases (CKD) including PKD, driven by factor... Full story

Yahoo Finance • 10 days ago

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story

Yahoo Finance • 18 days ago

I Examined More Than 100 U.S. Dividend ETFs. This One Delivers the Best Risk-Adjusted Returns.

Dividend stocks have enjoyed a bit of a renaissance this year. They're also coming off three years where they deeply underperformed the S&P 500(SNPINDEX: ^GSPC). Different stocks perform well in different environments, of course, but absol... Full story

Yahoo Finance • 21 days ago

Most healthcare companies report higher Y/Y EPS in strong earnings week

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare companies delivered strong earnings this week, with 18 out of 20 companies beating EPS estimates and 15 t... Full story

Yahoo Finance • 23 days ago

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) came out with its first-quarter results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. The result w... Full story

Yahoo Finance • 24 days ago

Is It Too Late To Consider Vertex Pharmaceuticals (VRTX) After Recent Share Price Weakness

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Wondering if Vertex Pharmaceuticals at around US$424 per share is still a solid opportunity or if the easy gains are behind... Full story

Yahoo Finance • 24 days ago

NKF Honors Vertex with 2026 Kidney Biotech Innovation Award

Company recognized for exceptional leadership in redefining what is possible in kidney disease treatment through true disease-modifying innovation. NEW YORK, May 6, 2026 /PRNewswire/ -- Vertex has been selected to receive the 2026 Kidney... Full story

Yahoo Finance • 25 days ago

US Equity Futures Higher Pre-Bell as Traders Keep Eye on Potential Re-Escalation of Middle East Hostilities

US equity futures were higher pre-bell Tuesday as traders kept a close watch on the potential re-esc PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 26 days ago

Vertex (VRTX) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Aug. 4, 2025 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Reshma KewalramaniChief Commercial Officer — Duncan McKechnieChief Financial Officer — Charles F. Wagner Need a quote from a... Full story

Yahoo Finance • 27 days ago

How Investors Are Reacting To Vertex (VRTX) FDA ALYFTREK Expansion and Evolving Pipeline Story

Recently, Vertex Pharmaceuticals reported that director Suketu Upadhyay will leave its board at the 2026 annual meeting while the US FDA approved expanded use of ALYFTREK for cystic fibrosis patients aged 6 and older. At the same time, Ban... Full story

Yahoo Finance • 28 days ago

Halozyme (HALO) Rated Buy on Strong Royalty Growth

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Hal... Full story

Yahoo Finance • 28 days ago

Vertex (VRTX) Named Top Biotech Pick for 2026 by BofA

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the most profitable biotech stocks to buy now. On April 13, Bank of America reiterated Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as a top large-cap biotech pick for 2026... Full story

Yahoo Finance • 28 days ago

Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard

[Magnifying Glass On Top Of Bar Chart] DNY59 Out of 22 S&P 500 healthcare companies that reported results this week, 19 beat earnings expectations and 15 posted year-over-year EPS growth. All 22 companies recorded year-over-year revenue i... Full story

Yahoo Finance • 28 days ago

Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying?

Key Points These companies are facing several challenges. However, both have attractive opportunities ahead. Patient investors who buy their shares today could be rewarded. 10 stocks we like better than Intuitive Surgical › Intuitive S... Full story

Yahoo Finance • last month

IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight

DelveInsight Business Research LLP The IgAN market is growing due to rising prevalence, improved diagnostics, novel immunotherapies, ongoing clinical trials of therapies such as Zigakibart (Novartis), Sefaxersen (F. Hoffmann-La Roche/Ioni... Full story

Yahoo Finance • last month

Conestoga Capital Advisors Exited Vertex (VRTX) as the Valuation No Longer Reflects a Favorable Risk-Reward

Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 began with optimism about the domestic economy and attractive... Full story

Yahoo Finance • last month

Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV). Over the next few years, therap... Full story